Two susceptibility loci identified for prostate cancer aggressiveness.
about
A comparison of genetic risk score with family history for estimating prostate cancer riskProstate cancer characteristics in the World Trade Center cohort, 2002-2013Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer PhenotypesIdentification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray AnalysisPutative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.The chromosome 3q26 OncCassette: A multigenic driver of human cancer.Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.CD24 is a genetic modifier for risk and progression of prostate cancer.Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers.Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.Does true Gleason pattern 3 merit its cancer descriptor?Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study.Genetic predisposition to prostate cancer.A prospective study of mitochondrial DNA copy number and the risk of prostate cancer.Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.A multi-locus genetic association test for a dichotomous trait and its secondary phenotype.Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21.Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans.Intersecting transcriptomic profiling technologies and long non-coding RNA function in lung adenocarcinoma: discovery, mechanisms, and therapeutic applications.Analysis of Tumor Biology to Advance Cancer Health Disparity Research.Evidence for Very Recent Positive Selection in Mongolians.Co-expression and significance of Dok2 and Ras p21 protein activator 1 in breast cancer.Genome-wide association studies of cancer: current insights and future perspectives.Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.
P2860
Q26752649-C171EBEA-BB88-4FE8-8ED9-2F7DC60C9362Q28065062-2CBD2303-B9F7-46E7-A122-FD3FC6EBF15CQ30240027-8CEB42E7-339A-4061-8255-3D673C6A6742Q33565740-21721054-1385-4D4A-B926-01759587448AQ36150385-022200E5-6499-4486-86CC-558B90D4244AQ36469793-880BF193-B885-4536-BFE3-080FF84CDFADQ36510237-0B98C3BA-91CE-4F14-A607-08A5E575C669Q37179254-EF03EDA0-A78C-4D4F-B4A9-9B7F627F7BF3Q37264491-FFFAC104-AF14-45FF-A8FE-FB6351C910BCQ37548751-614EB019-D595-483C-99CA-5CD5DA11B686Q37622580-B8591F41-2976-4AFF-87FD-19D059BFF5ADQ37686900-A7C2047F-E257-48E8-80ED-98A5A9FF75C5Q38371012-E72913B4-B782-4D5C-8366-79F6842379A1Q38402430-2FCB65C0-C50E-4DE5-AE6D-EE87AFD134ECQ38547110-2EBBEA59-6EAF-41A6-BDC5-D940A9C0B08FQ38683029-C14F3FC7-31C2-42AF-BB0E-2F1B3D37BAA5Q38928930-966EE21D-0E2D-4B39-AA4A-6CB0849588A3Q39002788-A65C3BAA-F216-4581-97A1-A62D0FBB73DEQ39035687-410183C0-DBB1-4D1B-BB2A-9CD2B3F68156Q40267482-5E05909D-D3BB-4020-8771-07CD892DFC3CQ40625323-AEFA4B50-1C0F-4B11-8B40-0F6441AF1A9DQ40628904-B17B615F-9601-4B67-839C-9809A049A8B5Q40718874-2B06F23D-9DC0-4DE2-B14A-4B3C69368D6CQ42731004-AA97911F-27C3-41B3-8CD0-889A0D70F643Q46077218-C2D379EA-BE78-4E9F-B180-5E054BA83A03Q46324231-606E5023-917D-499E-8020-7BE4125E81A6Q46376521-1C4B6A60-2D86-4981-86F9-82E877A99112Q47143266-09748CA4-BE17-40DF-A0F2-B33D3CECE94DQ47900293-5B89A7A0-D781-489F-A803-40A2D90FAD1FQ52645860-556E6E8A-329A-438F-BCB8-BFC56889EBCCQ53146034-D64523B6-B02F-4F35-B7E7-19B397BF5573Q55265680-B7C82EB4-9EEB-44D4-8FD5-118969EA65C3
P2860
Two susceptibility loci identified for prostate cancer aggressiveness.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Two susceptibility loci identified for prostate cancer aggressiveness.
@ast
Two susceptibility loci identified for prostate cancer aggressiveness.
@en
type
label
Two susceptibility loci identified for prostate cancer aggressiveness.
@ast
Two susceptibility loci identified for prostate cancer aggressiveness.
@en
prefLabel
Two susceptibility loci identified for prostate cancer aggressiveness.
@ast
Two susceptibility loci identified for prostate cancer aggressiveness.
@en
P2093
P2860
P50
P356
P1476
Two susceptibility loci identified for prostate cancer aggressiveness.
@en
P2093
African Ancestry Prostate Cancer GWAS Consortium
Amanda Black
Daniele Campa
Fred Schumacher
Fredrik Wilkund
Gerald Andriole
Janet L Stanford
Jean-Nicolas Cornu
Joshua Sampson
P2860
P2888
P356
10.1038/NCOMMS7889
P407
P50
P577
2015-05-05T00:00:00Z